Charles Schwab Investment Management Inc. Acquires 37,714 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Charles Schwab Investment Management Inc. increased its stake in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 4.8% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 827,545 shares of the company's stock after acquiring an additional 37,714 shares during the period. Charles Schwab Investment Management Inc. owned about 0.81% of Intellia Therapeutics worth $17,006,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of NTLA. Blue Trust Inc. increased its position in Intellia Therapeutics by 1,664.3% during the second quarter. Blue Trust Inc. now owns 1,482 shares of the company's stock worth $33,000 after buying an additional 1,398 shares during the last quarter. EverSource Wealth Advisors LLC raised its stake in Intellia Therapeutics by 763.5% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,753 shares of the company's stock valued at $39,000 after acquiring an additional 1,550 shares during the period. Eastern Bank acquired a new stake in Intellia Therapeutics during the 3rd quarter valued at $41,000. First Horizon Advisors Inc. raised its position in shares of Intellia Therapeutics by 22.1% in the second quarter. First Horizon Advisors Inc. now owns 2,604 shares of the company's stock valued at $58,000 after purchasing an additional 472 shares during the period. Finally, Values First Advisors Inc. bought a new stake in shares of Intellia Therapeutics during the 3rd quarter worth about $54,000. 88.77% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Intellia Therapeutics

In other news, CAO Michael P. Dube sold 2,012 shares of the company's stock in a transaction on Wednesday, October 2nd. The shares were sold at an average price of $19.01, for a total transaction of $38,248.12. Following the completion of the transaction, the chief accounting officer now directly owns 47,012 shares in the company, valued at approximately $893,698.12. This represents a 4.10 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 3.20% of the company's stock.

Intellia Therapeutics Price Performance

Shares of NTLA stock traded up $1.07 on Friday, hitting $14.72. 2,821,292 shares of the company's stock were exchanged, compared to its average volume of 2,724,545. The company has a 50 day moving average of $16.61 and a 200 day moving average of $20.94. The stock has a market cap of $1.50 billion, a P/E ratio of -2.71 and a beta of 1.76. Intellia Therapeutics, Inc. has a 12 month low of $12.82 and a 12 month high of $34.87.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($1.34) earnings per share for the quarter, beating analysts' consensus estimates of ($1.37) by $0.03. The company had revenue of $9.10 million during the quarter, compared to analyst estimates of $8.28 million. The company's revenue for the quarter was down 24.1% on a year-over-year basis. During the same quarter in the previous year, the business posted ($1.38) earnings per share. Sell-side analysts predict that Intellia Therapeutics, Inc. will post -5.12 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the stock. StockNews.com upgraded shares of Intellia Therapeutics to a "sell" rating in a research report on Friday, November 8th. Wedbush reissued a "neutral" rating and set a $14.00 price target on shares of Intellia Therapeutics in a report on Monday, November 18th. Canaccord Genuity Group reaffirmed a "buy" rating and issued a $90.00 price objective on shares of Intellia Therapeutics in a report on Tuesday, November 19th. William Blair reiterated a "neutral" rating and set a $14.00 price objective on shares of Intellia Therapeutics in a research report on Monday, November 18th. Finally, Chardan Capital upped their price target on shares of Intellia Therapeutics from $88.00 to $91.00 and gave the company a "buy" rating in a research note on Monday, November 18th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Intellia Therapeutics currently has an average rating of "Moderate Buy" and an average target price of $54.94.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.